Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

  • ID: 3821693
  • Company Profile
  • 119 pages
  • Global Markets Direct
1 of 4
Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

Summary

‘Chugai Pharmaceutical Co., Ltd. - Product Pipeline Review, 2016’, provides an overview of the Chugai Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Chugai Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Chugai Pharmaceutical Co., Ltd.
- The report provides overview of Chugai Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Chugai Pharmaceutical Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Chugai Pharmaceutical Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Chugai Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chugai Pharmaceutical Co., Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chugai Pharmaceutical Co., Ltd.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Figures

Chugai Pharmaceutical Co., Ltd. Snapshot

Chugai Pharmaceutical Co., Ltd. Overview

Key Information

Key Facts

Chugai Pharmaceutical Co., Ltd. - Research and Development Overview

Key Therapeutic Areas

Chugai Pharmaceutical Co., Ltd. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Chugai Pharmaceutical Co., Ltd. - Pipeline Products Glance

Chugai Pharmaceutical Co., Ltd. - Late Stage Pipeline Products

Phase III Products/Combination Treatment Modalities

Chugai Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Chugai Pharmaceutical Co., Ltd. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Chugai Pharmaceutical Co., Ltd. - Drug Profiles

atezolizumab

Product Description

Mechanism of Action

R&D Progress

bevacizumab

Product Description

Mechanism of Action

R&D Progress

eldecalcitol

Product Description

Mechanism of Action

R&D Progress

gantenerumab

Product Description

Mechanism of Action

R&D Progress

lebrikizumab

Product Description

Mechanism of Action

R&D Progress

obinutuzumab

Product Description

Mechanism of Action

R&D Progress

SA-237

Product Description

Mechanism of Action

R&D Progress

tocilizumab

Product Description

Mechanism of Action

R&D Progress

codrituzumab

Product Description

Mechanism of Action

R&D Progress

nemolizumab

Product Description

Mechanism of Action

R&D Progress

basmisanil

Product Description

Mechanism of Action

R&D Progress

EOS-789

Product Description

Mechanism of Action

R&D Progress

PCO-371

Product Description

Mechanism of Action

R&D Progress

polatuzumab vedotin

Product Description

Mechanism of Action

R&D Progress

RG-7304

Product Description

Mechanism of Action

R&D Progress

taselisib

Product Description

Mechanism of Action

R&D Progress

CH-5036249

Product Description

Mechanism of Action

R&D Progress

CH-5164840

Product Description

Mechanism of Action

R&D Progress

CH-5449302

Product Description

Mechanism of Action

R&D Progress

CH-5451098

Product Description

Mechanism of Action

R&D Progress

CVE-199

Product Description

Mechanism of Action

R&D Progress

ERY-974

Product Description

Mechanism of Action

R&D Progress

maxacalcitol

Product Description

Mechanism of Action

R&D Progress

NA-255

Product Description

Mechanism of Action

R&D Progress

Recombinant Protein to Agonize PTHR1 for Hypoparathyroidism

Product Description

Mechanism of Action

R&D Progress

gMSC-1

Product Description

Mechanism of Action

R&D Progress

Chugai Pharmaceutical Co., Ltd. - Pipeline Analysis

Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Target

Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration

Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type

Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action

Chugai Pharmaceutical Co., Ltd. - Recent Pipeline Updates

Chugai Pharmaceutical Co., Ltd. - Dormant Projects

Chugai Pharmaceutical Co., Ltd. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

nitazoxanide

basimglurant

bevacizumab

hyaluronate sodium

NA-808

onartuzumab

orlistat

PA-799

parsatuzumab

pictilisib

RG-7167

sembragiline

tocilizumab

trastuzumab emtansine

Chugai Pharmaceutical Co., Ltd. - Company Statement

Chugai Pharmaceutical Co., Ltd. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Chugai Pharmaceutical Co., Ltd., Key Information

Chugai Pharmaceutical Co., Ltd., Key Facts

Chugai Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016

Chugai Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016

Chugai Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016

Chugai Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016

Chugai Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016

Chugai Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016

Chugai Pharmaceutical Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016

Chugai Pharmaceutical Co., Ltd. - Phase III, 2016

Chugai Pharmaceutical Co., Ltd. - Phase II, 2016

Chugai Pharmaceutical Co., Ltd. - Phase I, 2016

Chugai Pharmaceutical Co., Ltd. - Preclinical, 2016

Chugai Pharmaceutical Co., Ltd. - Discovery, 2016

Chugai Pharmaceutical Co., Ltd. - Pipeline by Target, 2016

Chugai Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016

Chugai Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016

Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016

Chugai Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2016

Chugai Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016

Chugai Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2016

Chugai Pharmaceutical Co., Ltd., Other Locations

Chugai Pharmaceutical Co., Ltd., Subsidiaries 116List of Figures

Chugai Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2016

Chugai Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016

Chugai Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016

Chugai Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2016

Chugai Pharmaceutical Co., Ltd. - Out-Licensed Products in Pipeline, 2016

Chugai Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2016

Chugai Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016

Chugai Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016

Chugai Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll